Novel Multifunctional Nanoagent for Visual Chemo/Photothermal Therapy of Metastatic Lymph Nodes via Lymphatic Delivery

Cheng, Juan; Liu, Ying; He, Lingyun; Liu, Weiwei; Chen, Yuli; Liu, Fengqiu; Guo, Yuan; Ran, Haitao; Lu, Yang

doi:10.1021/acsomega.9b03258

Cited by 6 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, PTT combined with chemotherapy was explored for the ablation of metastatic lymph nodes via lymphatic delivery. [ 31 ] In this study, we also found the TiN nanoshells readily drain into the lymph nodes when they are injected around the primary tumor, similar as the carbon nanoparticles used clinically. Therefore, we used the TiN nanoshells for the lymphatic delivery of CFZ and assessed the potential for the treatment of cancer with lymphatic metastatic spread.…”

Section: Introductionsupporting

confidence: 53%

Chemo‐Phototherapy with Carfilzomib‐Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis

Wang

et al. 2022

Small

View full text Add to dashboard Cite

in combination with adjuvant chemotherapy is commonly applied at the early stage of cancer, but subsequent relapse and metastasis always lead to a poor clinical outcome. During cancer metastasis, sentinel lymph nodes (SLNs) near the tumors are usually the first site through which the cancer cells spread to lung, liver and other vital organs. [1] To address these challenges, great efforts have been devoted to developing novel anticancer drugs and nanosized drug delivery systems for suppressing both primary tumor growth and lymphatic metastasis.Protein degradation has become an attractive target for chemotherapy. Ubiquitin-proteasome system (UPS) and autophagy are two major routes responsible for the degradation of intracellular proteins and organelles. [2] More than 80% of cellular proteins including misfolded and damaged proteins are cleaned by UPS. Disruption of protein homeostasis by inhibition of proteasome attenuates multiple signaling pathways involved in tumor transformation. [3] Bortezomib and carfilzomib (CFZ) are the first-and second-generation of clinically approved proteasome inhibitors, respectively. [4] Due to the poor aqueous solubility of CFZ, sulfobutyl ether β-cyclodextrin as a solubilizer is needed to make CFZ injectable. Recently, The design of nanomedicine for cancer therapy, especially the treatment of tumor metastasis has received great attention. Proteasome inhibition is accepted as a new strategy for cancer therapy. Despite being a big breakthrough in multiple myeloma therapy, carfilzomib (CFZ), a second-in-class proteasome inhibitor is still unsatisfactory for solid tumor and metastasis therapy. In this study, hollow titanium nitride (TiN) nanoshells are synthesized as a drug carrier of CFZ. The TiN nanoshells have a high loading capacity of CFZ, and their intrinsic inhibitory effect on autophagy synergistically enhances the activity of CFZ. Due to an excellent photothermal conversion efficiency in the second near-infrared (NIR-II) region, TiN nanoshell-based photothermal therapy further induces a synergistic anticancer effect. In vivo study demonstrates that TiN nanoshells readily drain into the lymph nodes, which are responsible for tumor lymphatic metastasis. The CFZ-loaded TiN nanoshell-based chemo-photothermal therapy combined with surgery offers a remarkable therapeutic outcome in greatly inhibiting further metastatic spread of cancer cells. These findings suggest that TiN nanoshells act as an efficient carrier of CFZ for realizing enhanced outcomes for proteasome inhibitor-based cancer therapy, and this work also presents a "combined chemo-phototherapy assisted surgery" strategy, promising for future cancer treatment.

show abstract

Section: Introductionsupporting

confidence: 53%

Chemo‐Phototherapy with Carfilzomib‐Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis

Wang

et al. 2022

Small

View full text Add to dashboard Cite

show abstract

“…Tumour cells metastasise in vivo in several ways, including directly invading surrounding tissues, transferring to distant organs through blood (vascular metastasis), and reaching lymph nodes and distant organs through the lymphatic system (lymphatic metastasis) 9 . Lymphatic metastasis is one of the predominant metastatic pathways for most tumour metastasis 10 and occurs early during tumour development 11 . According to the previous reports, PTX could activate toll-like receptor-4 (TLR4) to enhance systemic inflammation and promote lymphangiogenesis and breast cancer lymphatic metastasis 12 .…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis

Zhang¹,

Zhu²,

Yao³

et al. 2022

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Chemotherapeutic drugs have been successfully used to treat several cancers, including melanoma. However, metastasis occasionally occurs after chemotherapy. Here, we reported that paclitaxel (PTX) treatment for B16F10 tumour in mice led to an enhanced lymphatic metastasis of the melanoma cells, although a significant inhibition of tumour growth at the injection site was observed. Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways. Loss of CCR7 or blockade of C-C motif chemokine ligand 21 (CCL21)/CCR7 axis abolished the pro-migration effect of PTX on B16F10 melanoma cells. Importantly, combination of PTX and CCR7 mAb could simultaneously delay the tumour growth and reduce the lymphatic metastasis in B16F10 melanoma. The blockade of CCL21/CCR7 axis may collectively serve as a strategy for lymphatic metastasis in some melanoma after chemotherapy.

show abstract

“…Tumour blood flow quantification was classified according to the Adler semi-quantitative method (Levels 0-I are classified as benign lesions, and Levels II-III are classified as malignant lesions). 7 Spectral measurements were performed using pulsed-wave Doppler ultrasound.…”

Section: Methodsmentioning

confidence: 99%

Fibro-Adipose Vascular Anomaly: Characteristic Imaging Features on Sonography and Magnetic Resonance Imaging

Gong

et al. 2022

Vasc Endovascular Surg

View full text Add to dashboard Cite

Objective To analyse the image characteristics of fibro-adipose vascular anomaly (FAVA) and the value of ultrasound and magnetic resonance imaging (MRI) for its diagnosis. Methods The clinical and imaging data characteristics of 10 patients with FAVA admitted to our hospital between January 2018 and December 2020 who underwent ultrasound and MRI diagnosis were retrospectively analysed. Results A total of 10 patients (six males and four females) with pathologically confirmed FAVA, aged from 3 to 27 years (median: 13 years), underwent ultrasound and MRI; of these, two patients underwent MRI-enhanced examinations. All lesions involved mainly muscle, with a few disruptions and involvements of subcutaneous fat. Five cases were located subcutaneously near the fascia; one case was adjacent to the periosteum. Ultrasound showed fascial tail in seven cases, and MRI showed fascial tail in six cases. Both ultrasound and MRI showed the lesions to be oval-shaped masses with blurred borders and a mean maximum diameter of 99.8 ± 48.7 mm. Ultrasound showed a mass with a mixture of high and low echoic areas. Magnetic resonance imaging imaging showed a heterogeneous, mixed-signal intensity on T1-weighted images, probably influenced by the fibrous and fatty components of the lesion. T2-weighted images showed a mixed-high signal. Enhanced computed tomography scans showed significant heterogeneous enhancement of the lesions. Conclusion Both ultrasound and MRI showed that fascial tail sign is an important imaging feature for FAVA disease; this provides a reliable basis for its diagnosis and can be used to distinguish it from venous malformations, which have no fascial tail signs. Therefore, fascial tail signs can be used as imaging features and require special attention in the diagnosis of FAVA disease.

show abstract

Novel Multifunctional Nanoagent for Visual Chemo/Photothermal Therapy of Metastatic Lymph Nodes via Lymphatic Delivery

Cited by 6 publications

References 48 publications

Chemo‐Phototherapy with Carfilzomib‐Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis

Chemo‐Phototherapy with Carfilzomib‐Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis

Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis

Fibro-Adipose Vascular Anomaly: Characteristic Imaging Features on Sonography and Magnetic Resonance Imaging

Contact Info

Product

Resources

About